Thomas O. Hecht
Chairman at AFFIMED N.V.
Net worth: 13 M $ as of 2024-03-30
Profile
Dr. Thomas O.
Hecht, MD, is an Independent Director at BioInvent International AB, a Chairman at Orion Biotechnology Canada Ltd., a Chairman-Supervisory Board at Affimed GmbH, a Chairman-Supervisory Board at Affimed NV, a Chairman-Supervisory Board at Affimed AG, a Chairman at Aelix Therapeutics SL and a President & Director at Haemosan, Inc. He is on the Board of Directors at BioInvent International AB and Haemosan, Inc. Dr. Hecht was previously employed as a Chairman by Vaximm AG, a Non-Executive Director by Kuur Therapeutics Ltd., an Executive Chairman by Delenex Therapeutics AG, a Chairman by ESBATech, a Novartis Co. GmbH, an Executive Chairman by Cytos Biotechnology AG, a Founder by HHC consulting, a Vice President-Marketing by Amgen (Europe) GmbH, an Independent Director by IBEX Technologies, Inc., a Chairman by Lipideon Biotechnology AG, a Chairman-Supervisory Board by SuppreMol GmbH, a Chairman by Telormedix SA, and a Co-Head-Bone Marrow Transplantation Program by University of Freiburg.
He also served on the board at Humabs BioMed SA, Humabs BioMed SA, Société Générale de Financement du Québec and The Caisse de dépôt et placement du Québec.
He received his undergraduate degree from Sir George Williams University, a graduate degree from McGill University and a doctorate degree from the University of Freiburg.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
HAIVISION SYSTEMS, INC.
11.31% | 2023-03-12 | 3,268,352 ( 11.31% ) | 12 M $ | 2024-03-30 |
AFFIMED N.V.
0.23% | 2023-03-14 | 34,037 ( 0.23% ) | 180 396 $ | 2024-03-30 |
Thomas O. Hecht active positions
Companies | Position | Start |
---|---|---|
AFFIMED N.V. | Chairman | 2006-12-31 |
BIOINVENT INTERNATIONAL AB | Director/Board Member | 2020-07-02 |
Orion Biotechnology Canada Ltd.
Orion Biotechnology Canada Ltd. BiotechnologyHealth Technology Orion Biotechnology Canada Ltd. operates as pharmaceutical company. The company was founded by Rudolf Bom in 2011 and is headquartered in Ottawa, Canada. | Chairman | 2019-11-11 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Chairman | 2006-12-31 |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Chairman | 2017-07-31 |
Affimed AG | Chairman | 2004-12-31 |
Haemosan, Inc.
Haemosan, Inc. Regional BanksFinance Haemosan, Inc. operates as a bank holding company. The company was founded on August 20, 1979 and is headquartered in Mount-Royal, Canada. | President | - |
Former positions of Thomas O. Hecht
Companies | Position | End |
---|---|---|
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Chairman | 2020-06-29 |
Kuur Therapeutics Ltd.
Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Chairman | 2017-12-06 |
░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░ | ░░░░░░░░░░ |
Training of Thomas O. Hecht
University of Freiburg | Doctorate Degree |
McGill University | Graduate Degree |
Sir George Williams University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
AFFIMED N.V. | Health Technology |
BIOINVENT INTERNATIONAL AB | Health Technology |
Private companies | 19 |
---|---|
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | Finance |
IBEX Technologies, Inc.
IBEX Technologies, Inc. Medical SpecialtiesHealth Technology IBEX Technologies, Inc. manufactures and markets enzymes for biomedical use. The firm also specializes in the custom aliquoting, filling, and lyophilization of enzymes in diagnostic disposables for medical devices. Its products include glycobiology enzymes from flavobacterium heparinum, collagen assays, collagen antibodies, and diamine oxidase liquid. The company was founded by Robert A. Heft on April 10, 1972 and is headquartered in Montréal, Canada. | Health Technology |
Société Générale de Financement du Québec
Société Générale de Financement du Québec Investment ManagersFinance A department of the province of Québec, the Société Générale de Financement du Québec (SGF) provides development capital for businesses. They are headquartered in Montreal with offices in Québec and Saint-Hyacinthe. The firm was founded in 1962. | Finance |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
SuppreMol GmbH
SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Health Technology |
Kuur Therapeutics Ltd.
Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Health Technology |
Telormedix SA
Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | Health Technology |
Cell Medica Switzerland AG
Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Health Technology |
Amgen (Europe) GmbH | |
Haemosan, Inc.
Haemosan, Inc. Regional BanksFinance Haemosan, Inc. operates as a bank holding company. The company was founded on August 20, 1979 and is headquartered in Mount-Royal, Canada. | Finance |
Lipideon Biotechnology AG
Lipideon Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Lipideon Biotechnology AG engages in the provision of pharmaceutical activities. The company was founded on February 26, 2002 and is headquartered in Zurich, Switzerland. | Commercial Services |
Humabs BioMed SA
Humabs BioMed SA Miscellaneous Commercial ServicesCommercial Services Humabs BioMed SA is an antibody therapeutics biotechnology company. It develops human monoclonal antibody platforms for treatment of infectious and inflammatory diseases. The company was founded by Prof. Antonio Lanzavecchia on October 24, 2011 and is headquartered in Bellinzona, Switzerland. | Commercial Services |
HHC consulting | |
Affimed AG | |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Health Technology |
Orion Biotechnology Canada Ltd.
Orion Biotechnology Canada Ltd. BiotechnologyHealth Technology Orion Biotechnology Canada Ltd. operates as pharmaceutical company. The company was founded by Rudolf Bom in 2011 and is headquartered in Ottawa, Canada. | Health Technology |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
- Stock Market
- Insiders
- Thomas O. Hecht